The Hindu Business Line  Feb 2  Comment 
Drug-maker Lupin has launched a generic version of Santarus Inc’s Glumetza HCI extended release tablets in the US and secured a 180-day marketing exclusivity for the drug, the company said in an excha...
Motley Fool  Jul 16  Comment 
Why aren't investors celebrating Salix Pharmaceuticals's acquisition of Cosmo, and should they be?
DailyFinance  Jan 2  Comment 
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that it has completed its previously announced tender offer for all outstanding shares of common stock par value $0.0001 per share, including the associated rights to...
DailyFinance  Dec 30  Comment 
Santarus, Inc. (NASDAQ:SNTS) today announced that on December 20, 2013 it filed an amendment (the “Amendment”) to its Solicitation/Recommendation Statement on Schedule 14D-9 (the “Schedule 14D-9”), originally filed ...
DailyFinance  Dec 23  Comment 
Santarus, Inc. (NASDAQ: SNTS) today announced that it has begun patient enrollment in a multicenter, multinational, randomized, double-blind, placebo-controlled, multiple ascending dose study with the investigational...
Benzinga  Dec 17  Comment 
In a report published Tuesday, Stifel analyst Annabel Samimy downgraded the rating on Santarus (NASDAQ: SNTS) from Buy to Hold, and removed the $27.00 price target. In the report, Stifel noted, “Following the acquisition announcement by Salix...
Benzinga  Dec 17  Comment 
Analysts at Goldman Sachs downgraded Catamaran (NASDAQ: CTRX) from “conviction buy” to “neutral.” The target price for Catamaran is set to $50. Catamaran's shares closed at $46.15 yesterday. Analysts at Compass Point downgraded KB Home...
DailyFinance  Dec 10  Comment 
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) (“Salix”) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) in connection with Salix’s ...
StreetInsider.com  Dec 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Salix+Pharma+%28SLXP%29+Begins+Santarus+%28SNTS%29+Tender+Offer/8940836.html for the full story.
Reuters  Nov 26  Comment 
Salix Pharmaceuticals Ltd is planning to launch next week $1.35 billion in senior secured debt financing to fund its $2.6 billion acquisition of biopharmaceutical company...


Founded in 1996, Santarus Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of proprietary products and therapies that have the potential to treat gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). The company's main focus lies on the commercialization of proprietary immediate-release proton pump inhibitor (PPI) products. PPIs are the most frequently prescribed drugs for the treatment of many upper gastrointestinal (GI) diseases and disorders. Santarus offers the Zegerid family of products, which are proprietary immediate-release formulations that combine omeprazole, a PPI, and one or more antacids. These products are approved by the FDA for the treatment or reduction of the risk of a variety of upper GI diseases and disorders. Zegerid is currently marketed in capsule and powder for oral suspension dosage forms.

In 2006, Santarus earned $49.2 million in revenue, 93.4% of which came from product sales. Other revenues accounted for the balance 6.6%. Santarus has licensing agreements with two major pharmaceutical companies, Schering-Plough and GlaxoSmithKline, for Zegerid. Besides this, the company has co-promotion agreements for two products Naprelan and the EZ-Prep Bowel Cleansing system. Headquartered in San Diego, California, Santarus currently employs 347 people.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki